Archive
Week ahead: Shire continues pharma newsflow; Rolls-Royce results also key
Shire will complete the fourth-quarter results announcements from the FTSE 100-listed pharma giants following numbers from Astra and Glaxo
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 30 of 38
Investments and investor services
FTSE ends higher after tax cut pledge powers Wall St rally to record levels
FTSE 100 shares closed higher on Thursday in tandem with a US equity rally after President Donald Trump announced “phenomenal” corporate tax reform Wall Street had been waiting for with bated breath
US stocks recover from losses as analysts focus on surprise gasoline supply drop
US stocks recovered from intraday losses to end higher on Wednesday after analysts focused on a fall in gasoline inventories rather than a spike in oil supplies
Glaxo braces itself for £1bn Advair hit
Core earnings per share was 102.4p, at the top end of guidance for the year, but current year guidance was heavily caveated
Archive
Day Ahead: Sterling's slump could mask drab performance from Glaxo
Glaxo is the next pharmaceuticals giant to update the market and it will probably be a familiar story of increased competition from generic versions of its blockbuster drugs.
Archive
Week ahead: BP and Glaxo to continue trading trends for oil and drug giants
BP could please on Thursday as its recent quarterly updates have proved a little disappointing. GlaxoSmithKline will unveil its numbers Wednesday.
FTSE 100 shares sink as pound ascends on Trump disquiet
FTSE 100 stocks fell further below 7200 on Monday after sterling gained strength against the US dollar in the aftermath of President Donald Trump's inauguration speech
GlaxoSmithKline could receive further Brexit boost, says broker
That at least is the opinion of the respected pharma team at Jefferies, which raised its valuation of shares Europe’s largest drugs firm.
FTSE 100 shares hit 11th successive record high as sterling dips
FTSE 100 shares did it again on Thursday – the 11th successive record high close – as turbulence in sterling finally gave in to a further steady decline and helped push stocks higher. All except retailers, that is
Zak Mir tips three big names to do well in 2017
Mir has gone for giants in the oil, pharma and broadcasting sectors
Brexit and Trump key to how 2017 unfolds
Richard Hunter is keeping tabs on AstraZeneca, GSK and ITV as we head into 2017
GlaxoSmithKline’s fast-growing HIV drug business gets another boost
Glaxo has developed the new two-drug cocktail through its majority-owned ViiV Healthcare joint venture, in which US firm Pfizer and Japan’s Shionogi also hold stakes.
Investments and investor services
FTSE 100 ends above 7,000 for first time since late October
FTSE 100 shares closed back above 7,000 on Friday for the first time since late October
AstraZeneca top pick under UBS's new valuation method
The conventional forecasting tool-box is broken says the Swiss broker
Archive
Trending - fines, HSBC, JP Morgan, Pfizer and bird flu
A look at some of the big, trending topics on Wednesday
Five reasons to buy AstraZeneca
The general consensus is that the decline in AstraZeneca’s share price now represents a good buying opportunity
GlaxoSmithKline's shingles vaccine filed in Europe
Most sufferers are afflicted with a rash, but in the severest cases the disease can cause blindness and intense pain.
GlaxoSmithKline and Innoviva celebrate early FDA submission of COPD treatment
The closed triple combination therapy comprises three medicines delivered once-daily in GSK's Ellipta dry powder inhaler.
Risers and fallers: Fresnillo glistens, while Tate's in a state
Some of the main news-driven share price changes at 3.30pm.